Bayer's Oncology Momentum Collides With a Missouri Courtroom Still Holding the Wildcard

FDA clears Bayer's Hyrnuo for HER2-mutant NSCLC and Kerendia for type 1 diabetes CKD, while a $7.25 billion Roundup settlement awaits court approval.

Two regulatory green lights in barely a week have shifted Wall Street's attention toward Bayer's pharmaceutical engine — just as the company's most consequential legal question remains parked in a Missouri courtroom.

The FDA granted accelerated approval to Sevabertinib, marketed as Hyrnuo, as a first-line option for adults with locally advanced or metastatic non-squamous non-small cell lung cancer carrying an activating HER2/ERBB2-TKD mutation. Days later, the same agency cleared Finerenone (Kerendia) for a new indication: chronic kidney disease tied to type 1 diabetes. For a conglomerate long defined by its crop-science legacy, the twin nods mark a deliberate pivot toward oncology and specialty medicine.

HER2-mutant NSCLC ranks among the harder-to-treat subgroups, with a thin menu of therapeutic alternatives. Accelerated approval lets Bayer bring the drug to the US market before confirmatory trials wrap up — a regulatory shortcut that carries strings attached and is no guarantee of an immediate revenue pop. Even so, the decision signals that the pharma division keeps delivering while the legal machinery grinds on elsewhere.

A $7.25 Billion Settlement Still Waiting for a Signature

That machinery concerns Roundup. Bayer subsidiary Monsanto appeared before a Missouri court last Monday seeking approval of a $7.25 billion settlement covering a portion of the cancer claims tied to the weedkiller. Reuters reports the company faces roughly 65,000 lawsuits across US state and federal courts.

The hearing, originally slated for August, was pushed to September 14 to process opt-out revocation requests. A final judicial sign-off would make at least part of the legal exposure more calculable — but it has not arrived. The longer the delay, and the more plaintiffs exercise their right to opt out, the murkier the true financial burden beyond the settlement framework becomes.

Where the Stock Stands

Bayer shares changed hands at EUR 48.59, down 1.1% on the day, having shed 1.6% since the settlement hearing. The stock is trading just 0.4% above its 50-day moving average of EUR 48.40, with an RSI of 49.6 — neutral territory that offers no clear directional signal. On a 12-month view, the equity is up 78%, and it has climbed 33% since the start of the year. It sits 8.7% below its 52-week high of EUR 53.86, touched in early July.

The analyst community has taken notice. Barclays raised its price target on September 8 from EUR 60 to EUR 70 while reaffirming its Overweight rating. Deutsche Bank Research followed a day later, restating its Buy call with a EUR 60 target. Both houses see meaningful upside from current levels.

Debt, Guidance, and a Biofuel Side Bet

Management confirmed its 2026 full-year guidance and trimmed its net financial debt forecast to EUR 29–30 billion. On the agricultural side, Bayer and Neste struck a trading agreement to jointly scale newgold winter rapeseed for biofuel production — a reminder that the crop-science unit is not standing still even as its legal overhang dominates headlines.

Two Catalysts, One Verdict

The path forward hinges on whether the pipeline wins translate into actual revenue before the glyphosate uncertainty is fully retired. If the legal picture continues to clear, the pharma pipeline could become the stock's primary driver. If expectations of a swift final settlement approval sour — through a heavy opt-out rate or further postponements — the shares risk sliding back into their old role as a risk play.

The immediate test is the court's decision on the September 14 hearing, which has yet to be handed down. Until then, the stock hovers near its 50-day average — an equilibrium the next news impulse can shatter in either direction.